|
01/09/2023
|
Summary ToggleeGenesis and Eledon Pharmaceuticals Announce Collaboration for Use of Tegoprubart in Preclinical Xenotransplantation Studies
|
|
01/09/2023
|
Summary ToggleEledon Pharmaceuticals Provides Business and Pipeline Updates
|
|
12/21/2022
|
Summary ToggleC-Path's Transplant Therapeutics Consortium Receives EMA Qualification Opinion for iBox Scoring System
|
|
11/14/2022
|
Summary ToggleEledon Pharmaceuticals Reports Third Quarter 2022 Operating and Financial Results
|
|
11/03/2022
|
Summary ToggleEledon Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
|
|
10/24/2022
|
Summary ToggleEledon Pharmaceuticals Announces Upcoming Presentations at ASN’s Kidney Week 2022 and NEALS
|
|
10/03/2022
|
Summary ToggleEledon Pharmaceuticals to Participate in Two Upcoming Conferences
|
|
09/22/2022
|
Summary ToggleEledon Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference
|
|
09/06/2022
|
Summary ToggleEledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart in IgA Nephropathy
|
|
08/29/2022
|
Summary ToggleEledon Pharmaceuticals to Participate in Two Upcoming Investor Conferences
|
